Clinical Research Center of the Carolinas | Charleston, SC

Research site

(Unclaimed)

Location

1364 Ashley River Road, Charleston, South Carolina, United States of America

Site insights

Top conditions

Top treatments

Deucravacitinib

CTP-543

BI 730357

TAK-279

cemiplimab

BMS-986165

KX2-391

Cetaphil

CLS006

JTE-051

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 45 total trials

A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin

Subjects having mild-to-moderate crepiness, photodamage, and loss of firmness will apply a topical skincare regimen to the knees, thighs, hands, and...

Enrolling

Aging Skin

Photo-aged Skin

Drug: Cetaphil

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting

Plaque Psoriasis

Drug: Deucravacitinib Matching Placebo

Drug: JNJ-77242113 Matching Placebo

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Active, not recruiting

Plaque Psoriasis

Drug: TAK-279

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (Intrepid)

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling

Hidradenitis Suppurativa

Drug: Placebo

Drug: Lutikizumab

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants w...

Active, not recruiting

Lupus Erythematosus, Subacute Cutaneous

Lupus Erythematosus, Discoid

Drug: Deucravacitinib

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting

Plaque Psoriasis

Drug: Placebo

Drug: Apremilast

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting

Alopecia Areata

Drug: CTP-543

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE)

The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have bee...

Active, not recruiting

Psoriasis

Drug: Placebo

Drug: BMS-986165

Locations recently updated

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin...

Enrolling

Cutaneous Squamous Cell Carcinoma (CSCC)

Procedure: Standard of care

Drug: Cemiplimab

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-Rhod...

Active, not recruiting

Acne Vulgaris

Combination Product: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

Combination Product: 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-Rho...

Active, not recruiting

Superficial Basal Cell Carcinoma

Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

The aim of this study is to test the safety. tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel...

Active, not recruiting

Actinic Keratoses

Combination Product: BF-200 ALA and red light LED lamp

Combination Product: Vehicle and red light LED lamp